The US Food and Drug Administration has fully approved a new drug meant to slow down the progression of Alzheimer’s disease, allowing for the medicine’s wider insurance coverage.
Estimates suggest that more than 6.5 million adults of ages 65 and over in the US live with Alzheimer’s disease, which can slowly destroy people’s memory and thinking skills and eventually, their ability to carry out even simple everyday tasks.
